CEO & Executive ChairLynn Stockwell
Lynn Stockwell
Lynn Stockwell is our Chief Executive Officer and Executive Chair of the Board and is the managing member of the sponsor.
Ms. Stockwell is the founder of Bright Green Corporation (Nasdaq: BGXX), where she has been a board member
since its inception in 2019 and Chair of the Board since February 2024. From 2015 to 2020, Ms. Stockwell was
Managing Member of Bright Green Innovations, LLC, a pioneering plant-based pharmaceutical research company recognized for its compliance with federal legal standards. In this role, Ms. Stockwell expertly managed business, industry, and medical research relationships.
In addition to her leadership roles, Ms. Stockwell has also served as a director at a hospital, where she spearheaded fundraising initiatives advocating for the use of natural additives as a safer alternative to opioids. Her dedication extends to her sponsorship of biomedical research and clinical trials, particularly in the area of plant-based bio-identical hormone replacement. Ms. Stockwell’s commitment to healthcare innovation is further demonstrated by her membership in the Association for Healthcare Philanthropy (AHP).
Ms. Stockwell is also actively involved in advancing the professional development of women in the life sciences through her membership in the BioIndustry Association (BIA), where she focuses on scholarship opportunities. Additionally, she is a member of the National Breast Cancer Coalition, reflecting her commitment to impactful
healthcare advocacy.
Ms. Stockwell is the founder of Bright Green Corporation (Nasdaq: BGXX), where she has been a board member
since its inception in 2019 and Chair of the Board since February 2024. From 2015 to 2020, Ms. Stockwell was
Managing Member of Bright Green Innovations, LLC, a pioneering plant-based pharmaceutical research company recognized for its compliance with federal legal standards. In this role, Ms. Stockwell expertly managed business, industry, and medical research relationships.
In addition to her leadership roles, Ms. Stockwell has also served as a director at a hospital, where she spearheaded fundraising initiatives advocating for the use of natural additives as a safer alternative to opioids. Her dedication extends to her sponsorship of biomedical research and clinical trials, particularly in the area of plant-based bio-identical hormone replacement. Ms. Stockwell’s commitment to healthcare innovation is further demonstrated by her membership in the Association for Healthcare Philanthropy (AHP).
Ms. Stockwell is also actively involved in advancing the professional development of women in the life sciences through her membership in the BioIndustry Association (BIA), where she focuses on scholarship opportunities. Additionally, she is a member of the National Breast Cancer Coalition, reflecting her commitment to impactful
healthcare advocacy.
As Executive Chair, Lynn Stockwell contributes significantly to several key strategic areas:
Critical Role of Plant-Based Drugs
Ms. Stockwell supports initiatives that highlight the importance of plant-based drugs, which constitute about 45% of controlled substances, and are essential in modern therapeutic applications.
Historical Significance and Modern Use
She advocates for the responsible use of Schedule I and Schedule II plant-based controlled substances, which have been pivotal in both traditional and contemporary medicine.
Strategic Domestic Production
Ms. Stockwell focuses on the importance of U.S.-based cultivation and manufacturing to reduce dependency on foreign pharmaceutical sources.
Advanced Manufacturing Technologies
She promotes investment in cutting-edge technologies to enhance the domestic production of plant-based drugs, ensuring efficiency and safety.
Navigating Legal Landscapes
Ms. Stockwell addresses the complex regulatory environment of plant-based drugs to ensure compliance and promote innovation.
Innovative Drug Discovery
She leverages modern scientific advancements to discover and develop new plant-based drugs, maintaining the U.S. as a leader in pharmaceutical innovation.